Physician profile
David J Ermer
NPI 1205881331
$2,959.80
in general payments reported to CMS, 2019-2025
26 companies · $127 in 2025
The $127 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $806 · 2020: $309 · 2021: $570 · 2022: $459 · 2023: $648 · 2024: $40.63 · 2025: $127.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $816.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $816.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $386.38 | 2019-2023 | Rexulti, Abilify Maintena |
| Janssen Pharmaceuticals, INC | $362.15 | 2019-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Corium, LLC | $227.21 | 2023-2024 | Azstarys |
| Jazz Pharmaceuticals INC. | $195.66 | 2019-2022 | |
| Lundbeck LLC | $195.48 | 2019-2022 | |
| Alkermes, INC. | $193.52 | 2019-2025 | Aristada, Lybalvi |
| Takeda Pharmaceuticals U.S.A., INC. | $185.71 | 2019-2023 | Trintellix |
| Supernus Pharmaceuticals, INC. | $134.90 | 2021-2023 | Qelbree |
| Shire North American Group INC | $123.14 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $107.51 | 2021-2022 | |
| Ironshore Pharmaceuticals INC. | $93.34 | 2019-2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $88.39 | 2020-2023 | |
| Merck Sharp & Dohme LLC | $83.27 | 2019-2023 | Belsomra |
| Vertical Pharmaceuticals, LLC | $74.41 | 2019-2020 | |
| Tris Pharma INC | $73.01 | 2021-2023 | Dyanavel Xr |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neos Therapeutics, Lp | $61.86 | 2019-2020 | |
| Avanir Pharmaceuticals, INC. | $57.40 | 2019-2021 | |
| Idorsia Pharmaceuticals US INC | $54.54 | 2023 | Quviviq |
| Harmony Biosciences LLC | $44.43 | 2022-2025 | |
| Sunovion Pharmaceuticals INC. | $44.26 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $39.19 | 2019-2021 | |
| Vanda Pharmaceuticals INC. | $37.05 | 2021 | |
| Acadia Pharmaceuticals INC | $33.57 | 2021-2023 | Nuplazid |
| Biogen, INC. | $24.71 | 2021 | |
| Axsome Therapeutics, INC. | $24.52 | 2023 | Auvelity |
| Indivior INC. | $14.19 | 2025 | Sublocade |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Ermer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.